In November Spineart hosted a lab in San Diego where 52 participants from the USA, Brazil, Mexico, Colombia, Chile, Slovakia and Malaysia had the opportunity to learn more about the latest innovations in total cervical disc replacement and anterior cervical discectomy fusion, management of adult scoliosis and minimally invasive treatment methods for degenerative conditions as well as benefits of sterile packaged barcoded implants.
All participants had the opportunity to train on M.I.S. surgical techniques through interactive presentations and hands-on anatomical workshops with the support of prominent surgeon faculty from the USA, Mexico, France & Germany. This was the largest international course hosted by Spineart to date.
Spineart is pleased to announce the world’s first implantation of the titanium version of the ROMEO®2 PAD, at the Lawrence + Memorial Hospital in New London, CT (USA).
ROMEO®2 PAD Ti is a Titanium posterior non pedicle supplemental fixation device intended for use as an adjunct to fusion in the lumbar spine.
Patrick F. Doherty, MD, neurosurgeon, successfully performed the procedure. After the surgery, Dr Doherty commented: “I have performed over 150 interspinous fusions since 2010. This device excels at allowing better placement against the spinous process due to the polyaxial nature of the implant, and provides better purchase into the spinous process due to the teeth pattern and height. ROMEO®2 PAD Ti provides an excellent alternative to pedicle screws via a midline, minimally invasive approach.”
All Spineart implants are sterile packed and bar-coded for increased safety, procedure compliance and cost effectiveness.
For more information, please contact us at email@example.com or visit spineart.com.
Spineart is pleased to announce the FDA approval of the SCARLET® AC-T cervical secured cage system. The SCARLET®AC-T combines the benefits of an interbody device and cervical plate in one implant. The locking mechanism of the screw head is completely integrated within the cage, reducing the profile and potential risks associated with dysphagia. The Titanium sandblasted surfaces of the implant facilitate primary stability and osseointegration.
The instrument set is designed according to Spineart’s philosophy of simplicity, featuring one compact box of intuitive instruments.
Spineart is pleased to announce the FDA approval for the ROMEO®2 PAD Posterior Axial Device, a posterior non pedicle supplemental fixation device intended for use as an adjunct to fusion in the lumbar spine.
The ROMEO®2 PAD Posterior Axial Device consists of two plates and a central core. It features 30° of plate poliaxiality, to adapt to the anatomy of the patient. The easy one-step locking mechanism allows the surgeon to compress, fix and lock the device at the same time. The instrument set follows the Spineart compact philosophy, featuring one box of intuitive instruments.
All Spineart implants are sterile packed and bar-coded for increased safety, procedure compliance and cost-efficiency.
Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.
Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies in the fields of Minimally Invasive Surgery, Motion Preservation, Fusion, Biologics, and Fractures Treatment.
Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital.
For more information please contact us at firstname.lastname@example.org or visit spineart.com.
We are pleased to announce the excellent results of a prospective observational study showing the safety and effectiveness of the BAGUERA®C cervical disc prosthesis. The device was evaluated 2 years postoperative, based on clinical and radiographical data of 118 patients with symptomatic cervical degenerative disc diseases (SCDDD), treated by total disc replacement (TDR) using the BAGUERA®C prosthesis. This study was conducted in 5 hospitals or clinics across France, Belgium, Spain, Germany and Greece.
The clinical and radiographical results showed that TDR using the BAGUERA®C device is:
– a safe procedure with low complication rate and no device-related adverse event
– an effective surgical treatment of single or double levels SCDDD, either used alone or in combination with other techniques (hybrid surgeries)
For both techniques (TDR-only and hybrid surgeries) the preservation of mobility and the disc height restoration at the implanted level were demonstrated. These results will be presented during the 2014 NASS meeting in San Francisco in November.
San Francisco, USA. Spineart is pleased to announce the first implantation of its lateral interbody device JULIET® LL in combination with the OTELO® MIS LATERAL Retractor.
Spineart has reached a new milestone, entering into the lateral approach market with an innovative full carbon fiber retractor that allows complete visualisation of the surgical site thanks to its radiolucent characteristics.
Dr Dimitriy Kondrashov, MD successfully performed the first case worldwide at St Mary Hospital in San Francisco. After the case, Dr Kondrashov commented: “The radiolucent design has allowed unparalleled visualization of the disk space and the placement of both the trials as well as the final implant under lateral fluoroscopic view. It made a very challenging multilevel degenerative scoliosis case safer and more straightforward. Being able to see the exact trial position has allowed me to avoid endplate violation and optimize anterior-to-posterior placement of the final lateral cages. I am looking forward to my next lateral case”.
All Spineart implants are sterile packaged and bar-coded for increased safety, traceability and cost-efficiency.
For more information, please contact us at email@example.com